Press

Mindbio Announces Major Diagnostic Speech Discovery

Jan 24 • 6 min read

Vancouver, British Columbia – TheNewswire – 21 January, 2025 – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6), (the “Company” or “MindBio”), a clinical stage biopharmaceutical company specialising in psychedelic microdosing today announced a major discovery in the effect of psychedelic microdosing on patient’s speech. The Company has discovered it can determine if a patient has dosed their medicine simply by analyzing their speech…

Filament Health Announces Shipment Of Botanical Psilocybin To The University of Wisconsin-Madison

Jan 24 • 3 min read

Vancouver, British Columbia, January 21, 2025 – Filament Health Corp. (OTCQB:FLHLF) (Cboe CA:FH) (FSE:7QS) (“Filament” or the “Company”), a clinical‐stage natural psychedelic drug development company, today announced that it has shipped its botanical psilocybin drug candidate, PEX010, to the University of Wisconsin–Madison (UW–Madison) for investigation in two clinical trials. Both trials are United States Food and Drug Administration…

Rua Bioscience Announces Support for Clinical Study That Harnesses the Potential of Psilocybin-Containing Mushrooms to Treat Methamphetamine Addiction

Jan 24 • 2 min read

Rua Bioscience announced its support for a clinical study that harnesses the potential of psilocybin-containing mushrooms to treat methamphetamine addiction. This pioneering research, rooted in an indigenous community and guided by mtauranga Mori, has reached a significant milestone. Over the past week, the first cohort of marae-based participants engaged in preparatory and experiential sessions with…

Awakn Announces Positive Outcome of Pre-IND Meeting with FDA for AWKN-002 in Alcohol Use Disorder

Jan 24 • 4 min read

Toronto, Ontario–(Newsfile Corp. – January 20, 2025) – Awakn Life Sciences Corp. (CSE: AWKN) (OTC Pink: AWKNF) (FSE: 954) (“Awakn” or the “Company”), a clinical-stage biotechnology company developing therapeutics for substance use and mental health disorders, announces a positive outcome from its Pre-Investigational New Drug (Pre-IND) meeting with the U.S. Food and Drug Administration (FDA), which took…

PharmAla To Supply Merhavim Mental Health Centre Clinical Trial in Exchange for Full Data License, in Partnership with MAPS Israel

Jan 20 • 3 min read

TORONTO, Jan. 20, 2025 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to announce that it has executed an agreement with Merhavim Mental Health Centre of…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441442443444445446447448